Eli Lilly (LLY)’s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant’s ability to now meet market demand. In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news.
Catalysts co-hosts Seana Smith and Brad Smith delve into the implications of this FDA action, analyzing how this development is likely to boost Eli Lilly’s operations.
For more expert insight and the latest market action, click here to watch this full episode of Catalysts.
This post was written by Angel Smith
